The Experts below are selected from a list of 942744 Experts worldwide ranked by ideXlab platform
Vincent Soriano - One of the best experts on this subject based on the ideXlab platform.
-
short communication does interleukin 28b single nucleotide polymorphisms influence the natural history of hepatitis b
AIDS Research and Human Retroviruses, 2012Co-Authors: Luz Martincarbonero, Norma Rallon, Jose M Benito, Eva Poveda, Juan Gonzalezlahoz, Vincent SorianoAbstract:Abstract Single nucleotide polymorphisms (SNP) nearby the IL28B gene have been associated with spontaneous hepatitis C virus (HCV) clearance and response to interferon-based therapies in both monoinfected and HIV-coinfected patients. However, its impact on spontaneous clearance of HBV (the pathogenesis of which is also related to interferon) is less known. A case-control study was performed. Cases were 49 HIV+ patients with chronic hepatitis B (HBsAg+ for more than 6 months) who had been genotyped for the rs12979860 SNP (protective CC genotype). One control for each case was chosen among HIV patients with anti-HBs and anti-HBc. Controls were matched for gender and coinfection with HCV. Most patients were male (90%) and the median (IQR) age was 42.6 (39–46.7) years. Eighteen (36.7%) were also coinfected by HCV. Among HBsAg+ patients, 19 (41.3%) were HBeAg+ and 13 (26.5%) were also infected with hepatitis delta (HDV). No differences were found in the distribution of the CC genotype between patients with chr...
-
viral hepatitis and HIV co infection
Antiviral Research, 2010Co-Authors: Vincent Soriano, Eugenia Vispo, Pablo Labarga, Jose Medrano, Pablo BarreiroAbstract:Abstract Chronic hepatitis B virus (HBV) infection is overall recognised in 10% of HIV+ persons worldwide, with large differences according to geographical region. Chronic hepatitis C virus (HCV) infection affects 25% of HIV+ individuals, with greater rates (∼75%) in intravenous drug users and persons infected through contaminated blood or blood products. HIV-hepatitis co-infected individuals show an accelerated course of liver disease, with faster progression to cirrhosis. The number of anti-HBV drugs has increased in the last few years, and some agents (e.g. lamivudine, emtricitabine, tenofovir) also exert significant activity against HIV. Emergence of drug resistance challenges the long-term benefit of anti-HBV monotherapy, mainly with lamivudine. The results using new more potent anti-HBV drugs (e.g. tenofovir) are very promising, with prospects for stopping or even revert HBV-related liver damage in most cases. With respect to chronic hepatitis C, the combination of pegylated interferon plus ribavirin given for 1 year permits to achieve sustained HCV clearance in no more than 40% of HIV–HCV co-infected patients. Thus, new direct anti-HCV drugs are eagerly awaited for this population. Although being a minority, HIV+ patients with delta hepatitis and those with multiple hepatitis show the worst prognosis. Appropriate diagnosis and monitoring of chronic viral hepatitis, including the use of non-invasive tools for assessing liver fibrosis and measurement of viral load, may allow to confront adequately chronic viral hepatitis in HIV+ patients, preventing the development of end-stage liver disease, for which the only option available is liver transplantation. This article forms part of a special issue of Antiviral Research marking the 25th anniversary of antiretroviral drug discovery and development, Vol 85, issue 1, 2010.
-
european aids clinical society eacs guidelines for the clinical management and treatment of chronic hepatitis b and c coinfection in HIV infected adults
Hiv Medicine, 2008Co-Authors: J K Rockstroh, Vincent Soriano, Sanjay Bhagani, Yves Benhamou, Raffaele Bruno, S Mauss, Lars Peters, Massimo Puoti, Cristina TuralAbstract:Objectives With the decline in HIV-associated morbidity and mortality following the introduction of highly active antiretroviral therapy (HAART), liver disease has emerged as a major cause of death in HIV/hepatitis B virus (HBV) and HIV/hepatitis C virus (HCV) coinfected persons. Therefore, screening for underlying viral hepatitis coinfection and the provision of management and treatment recommendations for patients with chronic viral hepatitis are of great importance in preventing, as far as possible, the development of liver disease. With the introduction of new agents for the treatment of hepatitis B and increased knowledge of how best to manage hepatitis C, an update of current guidelines for management of HBV and HCV coinfection with HIV is warranted. Summary Clearly, all HIV-infected patients should be screened for hepatitis A, B and C, taking into account shared pathways of transmission. Patients who are seronegative for hepatitis A and B should be considered for vaccination. In HIV-infected patients with chronic hepatitis B, the first important differentiation is whether HAART is required or not. In the setting of stable HIV infection, with no need for HAART, several treatment options are available, namely treatment with interferon, early initiation of HAART, or selective non-HIV active anti-HBV nucleoside therapy, with the aim of achieving undetectable HBV DNA levels. In most cases, undetectable HBV DNA can only be achieved with combination therapy. With regard to hepatitis C, individualized tailoring of the duration of HCV therapy is advisable, taking into account rapid or delayed virological response. In patients who do not achieve at least a 2 log drop in HCV RNA at week 12, treatment can be terminated because of the low probability of achieving sustained virological response. Overall, with the currently available treatment algorithms, HCV can be eradicated in over 50% of patients. Therefore, HCV therapy should be considered and discussed with the patient if an indication for HCV therapy (elevated liver enzymes, positive HCV RNA and >F1 fibrosis) is present. Conclusions Management of underlying hepatitis B and/or C in patients with HIV infection is of great importance in preventing liver disease-associated morbidity and mortality.
-
care of patients with chronic hepatitis b and HIV co infection recommendations from an HIV hbv international panel
AIDS, 2002Co-Authors: Vincent Soriano, Patrice Cacoub, Mark S Sulkowski, S Mauss, Colm Bergin, Angelos Hatzakis, Christine Katlama, Antonietta Cargnel, Douglas T Dieterich, Santiago MorenoAbstract:Liver disease caused by chronic hepatitis B virus (HBV) infection is currently an important cause of morbidity and mortality among HIV-infected patients in the western world where classical opportunistic complications of severe immunodeficiency have declined dramatically as a result of the widespread use of potent antiretroviral therapies. Over the past few years several consensus reports have addressed the issue of viral hepatitis and HIV co-infection. However as a result of the larger impact of hepatitis C virus (HCV) they have focused mainly on HIV and HCV co-infection whereas only a few reports have devoted particular attention to hepatitis B. There are several reasons to highlight HBV in HIV positive individuals. (excerpt)
Laurent Belec - One of the best experts on this subject based on the ideXlab platform.
-
usefulness of simultaneous screening for HIV specific and hcv specific antibodies and hbsag by a capillary based multiplex rapid diagnostic test to strengthen linkage to care in sub saharan patients attending sexually transmitted infection clinic
Journal of Medical Virology, 2018Co-Authors: Jean De Dieu Longo, Leman Robin, Ralphsydney Mboumba Bouassa, Laura Charmant, Marcel Mbeko Simaleko, Andre Kouabosso, Christian Diamant Mossorokpinde, Gerard Gresenguet, Laurent BelecAbstract:Adult outpatients attending the main sexually transmitted infection clinic of Bangui, Central African Republic, were prospectively subjected to a multiplex rapid diagnostic test for human immunodeficiency virus (HIV), hepatitis B virus (HBV), and hepatitis C virus (HCV). In group I (n = 208) of patients already followed for HIV, 6 (2.9%) were unexpectedly negative, thus corresponding to false positive for HIV by the national HIV algorithm; hepatitis B surface antigen and HCV positivities were high (18.7% and 4.3%, respectively). In group II (n = 71) of patients with unknown HIV status, at least 1 chronic viral disease was diagnosed in 26 (36.6%) patients, including 5 (7.1%) HIV, 17 (23.9%) HBV, and 3 (4.2%) HCV infections.
-
usefulness of simultaneous screening for HIV and hepatitis c specific antibodies and hepatitis b surface antigen by capillary based multiplex immunochromatographic rapid test to strengthen prevention strategies and linkage to care in childbearing aged women living in resource limited settings
Open Forum Infectious Diseases, 2018Co-Authors: Ralphsydney Mboumba Bouassa, Zita Aleyo Nodjikouambaye, Damtheou Sadjoli, Ali Mahamat Moussa, Chatte Adawaye, Donato Koyalta, Laurent BelecAbstract:Childbearing-aged women (n = 266) attending a gynecological clinic in Chad were subjected to multiplex immunochromatographic rapid test for HIV, hepatitis B virus (HBV), and hepatitis C virus (HCV). Ten (3.7%) and 8 (3.0%) were seropositive for HIV and HCV, respectively, and 20 (7.5%) for HBV surface antigen, allowing diagnosis of chronic viral infections in 1 of 7 (14.3%) women.
-
analytical performances of simultaneous detection of HIV 1 HIV 2 and hepatitis c specific antibodies and hepatitis b surface antigen hbsag by multiplex immunochromatographic rapid test with serum samples a cross sectional study
Journal of Virological Methods, 2018Co-Authors: Leman Robin, Ralphsydney Mboumba Bouassa, Zita Aleyo Nodjikouambaye, Laura Charmant, Mathieu Matta, Sylvie Simon, Mounir Filali, Souleymane Mboup, Laurent BelecAbstract:BACKGROUND The HIV/HCV/HBsAg Triplex consists in manually performed, visually interpreted, lateral flow, immunochromatographic rapid diagnostic test simultaneously detecting in 15min human immunodeficiency virus (HIV)-1 and HIV-2 and hepatitis C virus (HCV)- specific antibodies (Ab) (IgG and IgM) and hepatitis B virus (HBV) surface antigen (HBsAg) in serum, plasma and whole blood. METHODS A hospital-based cross-sectional study was conducted on a prospective panel of serum samples from adult inpatients included from routine analysis irrespectively of age and sex, including 250 sera positive for HIV-1-specific Ab, 250 for HCV-specific Ab, 250 for HBsAg and 250 sera negative for HIV- and HCV- Ab and HBsAg, and from 110 HIV-2-infected patients living in Ivory Coast, according to the results obtained by the reference chemiluminiscent microparticle immunoassay (CMIA) Abbott Architect i2000SR analyzer (Abbott Diagnostic, Chicago, IL, USA). Among HCV-seropositive sera, 187 were positive for HCV RNA (chronic infection), whereas 63 were negative (resolved infection), respectively. Serum samples were further tested blindly by HIV/HCV/HBsAg Triplex according to manufacturers' recommendations. RESULTS HIV/HCV/HBsAg Triplex showed very high sensitivity and specificity, as well as excellent concordance with CMIA Abbott results, as shown in the Table. Lower sensitivity was observed only in individuals who had cleared their HCV infection (presence of HCV-specific Ab in absence of HCV RNA). The mean lower limit of HBsAg detection was 2.38±0.63 IU/ml. Erythrocytes-spiked serum samples gave similar results than serum samples. CONCLUSIONS Advantages of HIV/HCV/HBsAg Triplex for HIV-1, HIV-2, HCV and HBV include the requirement for less overall specimen volume, fewer finger-sticks if capillary whole blood is used, cost savings through lower cost per virus tested, improved patient flow with results for multiple viruses available at the same time, overall service delivery efficiencies with less time required per infected patient; and patient benefits from fewer visits and lower cost associated with each clinic attendance. The screening of chronic HIV, HCV and HBV by multiplex HIV-1/HIV-2/HCV/HBsAg Triplex may improve the "cascade of screening" and quite possibly linkage-to-care with reduced cost.
Ralphsydney Mboumba Bouassa - One of the best experts on this subject based on the ideXlab platform.
-
usefulness of simultaneous screening for HIV specific and hcv specific antibodies and hbsag by a capillary based multiplex rapid diagnostic test to strengthen linkage to care in sub saharan patients attending sexually transmitted infection clinic
Journal of Medical Virology, 2018Co-Authors: Jean De Dieu Longo, Leman Robin, Ralphsydney Mboumba Bouassa, Laura Charmant, Marcel Mbeko Simaleko, Andre Kouabosso, Christian Diamant Mossorokpinde, Gerard Gresenguet, Laurent BelecAbstract:Adult outpatients attending the main sexually transmitted infection clinic of Bangui, Central African Republic, were prospectively subjected to a multiplex rapid diagnostic test for human immunodeficiency virus (HIV), hepatitis B virus (HBV), and hepatitis C virus (HCV). In group I (n = 208) of patients already followed for HIV, 6 (2.9%) were unexpectedly negative, thus corresponding to false positive for HIV by the national HIV algorithm; hepatitis B surface antigen and HCV positivities were high (18.7% and 4.3%, respectively). In group II (n = 71) of patients with unknown HIV status, at least 1 chronic viral disease was diagnosed in 26 (36.6%) patients, including 5 (7.1%) HIV, 17 (23.9%) HBV, and 3 (4.2%) HCV infections.
-
usefulness of simultaneous screening for HIV and hepatitis c specific antibodies and hepatitis b surface antigen by capillary based multiplex immunochromatographic rapid test to strengthen prevention strategies and linkage to care in childbearing aged women living in resource limited settings
Open Forum Infectious Diseases, 2018Co-Authors: Ralphsydney Mboumba Bouassa, Zita Aleyo Nodjikouambaye, Damtheou Sadjoli, Ali Mahamat Moussa, Chatte Adawaye, Donato Koyalta, Laurent BelecAbstract:Childbearing-aged women (n = 266) attending a gynecological clinic in Chad were subjected to multiplex immunochromatographic rapid test for HIV, hepatitis B virus (HBV), and hepatitis C virus (HCV). Ten (3.7%) and 8 (3.0%) were seropositive for HIV and HCV, respectively, and 20 (7.5%) for HBV surface antigen, allowing diagnosis of chronic viral infections in 1 of 7 (14.3%) women.
-
analytical performances of simultaneous detection of HIV 1 HIV 2 and hepatitis c specific antibodies and hepatitis b surface antigen hbsag by multiplex immunochromatographic rapid test with serum samples a cross sectional study
Journal of Virological Methods, 2018Co-Authors: Leman Robin, Ralphsydney Mboumba Bouassa, Zita Aleyo Nodjikouambaye, Laura Charmant, Mathieu Matta, Sylvie Simon, Mounir Filali, Souleymane Mboup, Laurent BelecAbstract:BACKGROUND The HIV/HCV/HBsAg Triplex consists in manually performed, visually interpreted, lateral flow, immunochromatographic rapid diagnostic test simultaneously detecting in 15min human immunodeficiency virus (HIV)-1 and HIV-2 and hepatitis C virus (HCV)- specific antibodies (Ab) (IgG and IgM) and hepatitis B virus (HBV) surface antigen (HBsAg) in serum, plasma and whole blood. METHODS A hospital-based cross-sectional study was conducted on a prospective panel of serum samples from adult inpatients included from routine analysis irrespectively of age and sex, including 250 sera positive for HIV-1-specific Ab, 250 for HCV-specific Ab, 250 for HBsAg and 250 sera negative for HIV- and HCV- Ab and HBsAg, and from 110 HIV-2-infected patients living in Ivory Coast, according to the results obtained by the reference chemiluminiscent microparticle immunoassay (CMIA) Abbott Architect i2000SR analyzer (Abbott Diagnostic, Chicago, IL, USA). Among HCV-seropositive sera, 187 were positive for HCV RNA (chronic infection), whereas 63 were negative (resolved infection), respectively. Serum samples were further tested blindly by HIV/HCV/HBsAg Triplex according to manufacturers' recommendations. RESULTS HIV/HCV/HBsAg Triplex showed very high sensitivity and specificity, as well as excellent concordance with CMIA Abbott results, as shown in the Table. Lower sensitivity was observed only in individuals who had cleared their HCV infection (presence of HCV-specific Ab in absence of HCV RNA). The mean lower limit of HBsAg detection was 2.38±0.63 IU/ml. Erythrocytes-spiked serum samples gave similar results than serum samples. CONCLUSIONS Advantages of HIV/HCV/HBsAg Triplex for HIV-1, HIV-2, HCV and HBV include the requirement for less overall specimen volume, fewer finger-sticks if capillary whole blood is used, cost savings through lower cost per virus tested, improved patient flow with results for multiple viruses available at the same time, overall service delivery efficiencies with less time required per infected patient; and patient benefits from fewer visits and lower cost associated with each clinic attendance. The screening of chronic HIV, HCV and HBV by multiplex HIV-1/HIV-2/HCV/HBsAg Triplex may improve the "cascade of screening" and quite possibly linkage-to-care with reduced cost.
Philippa C Matthews - One of the best experts on this subject based on the ideXlab platform.
-
prevalence and characteristics of hepatitis b virus hbv coinfection among HIV positive women in south africa and botswana
PLOS ONE, 2015Co-Authors: Philippa C Matthews, Apostolos Beloukas, Amna Malik, Jonathan M Carlson, Pieter Jooste, Anthony Ogwu, Roger L Shapiro, Lynn Riddell, Fabian Chen, Graz LuzziAbstract:There is progressive concern about the evolving burden of morbidity and mortality caused by coinfection with HIV-1 and hepatitis B virus (HBV) in sub-Saharan Africa, but the epidemiology and impact of this problem are not well defined. We therefore set out to assimilate more information about the nature of HBV/HIV coinfection in this region by undertaking a retrospective observational study of southern African adult women. We used samples from previously recruited HIV-1 positive women attending antenatal clinics in three settings in South Africa and Botswana (n = 950) and added a small cohort of HIV-negative antenatal South African women for comparison (n = 72). We tested for HBsAg and followed up HBsAg-positive samples by testing for HBeAg, HBV DNA, HBV genotype, presence of drug-resistance associated mutations (RAMs) and HDV. We identified HBsAg in 72 individuals (7% of the whole cohort), of whom 27% were HBeAg-positive, and the majority HBV genotypes A1 and A2. We did not detect any HDV coinfection. HBV prevalence was significantly different between geographically distinct cohorts, but did not differ according to HIV status. Among adults from South Africa, HBV/HIV coinfected patients had lower CD4+ T cell counts compared to those with HIV-monoinfection (p = 0.02), but this finding was not replicated in the cohort from Botswana. Overall, these data provide a snapshot of the coinfection problem at the heart of the HIV/HBV co-epidemic, and are important to inform public health policy, resource allocation, education, surveillance and clinical care.
-
epidemiology and impact of HIV coinfection with hepatitis b and hepatitis c viruses in sub saharan africa
Journal of Clinical Virology, 2014Co-Authors: Philippa C Matthews, Anna Maria Geretti, Philip J R Goulder, Paul KlenermanAbstract:Human immunodeficiency virus (HIV), Hepatitis B (HBV) and Hepatitis C (HCV) are blood-borne viruses with potentially shared routes of transmission. In high-income settings, the impact of antiretroviral therapy (ART) on survival has unmasked chronic liver disease from viral hepatitis B or hepatitis C as a leading cause of morbidity and mortality in individuals with HIV infection. It is now feared that progressive liver disease may threaten the success of ART programmes in developing countries, where HCV or HBV testing and monitoring are not yet systematic among HIV-infected patients and ART use is generally blind to these co-infections. We set out to review recent data from Sub-Saharan Africa, in order to build a detailed and up-to-date picture of the epidemiology and emerging impact of HBV and HCV coinfection in countries at the heart of the HIV pandemic. There is a preponderance of HIV/HBV coinfection compared to HIV/HCV in this region, and significant caveats exist regarding the accuracy of published HCV seroprevalence surveys. Morbidity and mortality of coinfection is significant, and may be further enhanced in African populations due to the influence of host, viral and environmental factors. Careful scrutiny of the coinfection problem is vital to inform an approach to directing resources, planning public health initiatives, providing clinical care, and guiding future research.
Shanchwen Chang - One of the best experts on this subject based on the ideXlab platform.
-
molecular epidemiology of hepatitis d virus infection among injecting drug users with and without human immunodeficiency virus infection in taiwan
Journal of Clinical Microbiology, 2011Co-Authors: Suiyuan Chang, Chialing Yang, Wenchun Liu, Chiying Lin, Shufang Chang, Maoyuan Chen, Wanghuei Sheng, Chienching Hung, Shanchwen ChangAbstract:An outbreak of human immunodeficiency virus (HIV) infection occurred among injecting drug users (IDU) in Taiwan between 2003 and 2006, when an extremely high prevalence of hepatitis C virus (HCV) infection was also detected. To determine whether clusters of hepatitis D virus (HDV) infection occurred in this outbreak, 4 groups of subjects were studied: group 1, HIV-infected IDU (n = 904); group 2, HIV-infected non-IDU (n = 880); group 3, HIV-uninfected IDU (n = 211); and group 4, HIV-uninfected non-IDU (n = 1,928). The seroprevalence of hepatitis B virus (HBV) was 19.8%, 18.4%, 17.1%, and 6.7%, and HDV seroprevalence among HBV carriers was 75.4%, 9.3%, 66.7%, and 2.3%, for groups 1, 2, 3, and 4, respectively. Ninety-nine of 151 (65.6%) HDV-seropositive IDU had HDV viremia: 5 were infected with HDV genotype I, 41 with genotype II, 51 with genotype IV, and 2 with genotypes II and IV. In the phylogenetic analysis, only one cluster of 4 strains within the HDV genotype II was identified. Among patients with HCV viremia, a unique cluster within genotype 1a was observed; yet, patients within this cluster did not overlap with those observed in the HDV phylogenetic analysis. In summary, although IDU had a significantly higher HDV seroprevalence, molecular epidemiologic investigations did not support that HDV was introduced at the same time as HCV among IDU.
-
impact of hepatitis d virus infection on the long term outcomes of patients with hepatitis b virus and HIV coinfection in the era of highly active antiretroviral therapy a matched cohort study
Clinical Infectious Diseases, 2007Co-Authors: Wanghuei Sheng, Suiyuan Chang, Maoyuan Chen, Chienching Hung, Jiahorng Kao, Szumin Hsieh, Peijer Chen, Shanchwen ChangAbstract:Triple infection with human immunodeficiency virus (HIV) hepatitis B virus (HBV) and hepatitis D virus (HDV) is rare. The influence of HDV infection on the responses to highly active antiretroviral therapy and hepatic complications in patients with HBV-HIV coinfection remains uncertain. Twenty-six HDV-infected case patients and 78 HDV-uninfected matched control subjects were identified between 1 January 1995 and 30 June 2003. Clinical and immunologic outcomes were noted and HBV and HIV loads and genotypic resistance of HBV to lamivudine were determined. Case patients had a higher rate of injection drug use (7.7% vs. 1.3%; P = .05) and lower serum levels of HBV DNA (median level 4.04 vs. 5.75 log10 copies/mL; P = .07) than control subjects. During a median observation period of 54.7 months HDV infection did not have an adverse impact on clinical virological or immunologic responses to highly active antiretroviral therapy. However case patients had higher rates of hepatitis flares (57.7% vs.23.1%; P = .002) hyperbilirubinemia (34.6% vs. 14.1%; P = .04) liver cirrhosis (26.9% vs. 5.1%; P = .009) hepatic decompensation (23.1% vs. 5.1%; P = .007) and death (adjusted hazard ratio 5.41; 95% confidence interval 1.39-23.85; P = .02) although these patients had a lower risk of genotypic resistance to lamivudine (0% vs. 57.1%; P = .003). HDV infection did not affect clinical virological or immunologic responses to highly active antiretroviral therapy in patients with HBV-HIV coinfection. HDV infection increased risk of hepatitis flares liver cirrhosis hepatic decompensation and death in patients with HBV-HIV coinfection. (authors)